Oren Hershkovitz
Chief Executive Officer at ENLIVEX THERAPEUTICS LTD.
Net worth: 27 778 $ as of 2024-04-29
Oren Hershkovitz active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Chief Executive Officer | 2019-11-15 | - |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Director/Board Member | 2016-08-31 | - |
Career history of Oren Hershkovitz
Training of Oren Hershkovitz
| Ben-Gurion University of the Negev | Doctorate Degree |
Statistics
International
| Israel | 4 |
Operational
| Chief Executive Officer | 1 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Private companies | 1 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
- Stock Market
- Insiders
- Oren Hershkovitz
- Experience
